BioCentury
ARTICLE | Company News

Chi-Med, Innovent enter global cancer partnership

December 7, 2018 7:13 PM UTC

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) and Innovent Biologics Inc. (HKSE:1801) will take advantage of China’s new foreign data guidelines and enter into a global partnership to develop fruquintinib in combination with sintilimab to treat advanced solid tumors.

The companies said the new foreign data guidelines, which allow companies to submit foreign clinical data to support Chinese regulatory submissions, could expedite the path to a China launch (see “China Accelerates Drug Review Timelines for Rare, Life-Threatening Diseases")...